Pharmaceutical companies are right to challenge the mandatory pricing model in court

Whether CMS has the authority to set drug prices based on foreign benchmarks is an open legal question.

From the articleTrump Administration Finalizes Plan to Lower Drug Prices in MedicareAlso in Trump's watered-down Medicare drug pricing rule saves 96% less than initial proposal, CMS finalizes model that aims to bring most-favored nation pricing to Part B